MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Quanterix Corp

Slēgts

SektorsVeselības aprūpe

6.23 -7.29

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.14

Max

6.7

Galvenie mērījumi

By Trading Economics

Ienākumi

-4.3M

-12M

Pārdošana

-249K

35M

EPS

-0.3

Peļņas marža

-33.07

Darbinieki

471

EBITDA

-3.8M

-15M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+115.77% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-107M

254M

Iepriekšējā atvēršanas cena

13.52

Iepriekšējā slēgšanas cena

6.23

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Quanterix Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. apr. 23:04 UTC

Top Ziņas

JPMorgan Raises Risk of U.S., Global Recession to 60%

2025. g. 3. apr. 22:40 UTC

Galvenie tirgus virzītāji

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

2025. g. 3. apr. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

2025. g. 3. apr. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

2025. g. 3. apr. 23:43 UTC

Tirgus saruna

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

2025. g. 3. apr. 23:41 UTC

Tirgus saruna

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

2025. g. 3. apr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 21:43 UTC

Top Ziņas
Peļņas

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. apr. 20:43 UTC

Tirgus saruna

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

2025. g. 3. apr. 20:34 UTC

Top Ziņas

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

2025. g. 3. apr. 20:23 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

2025. g. 3. apr. 19:21 UTC

Tirgus saruna

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

2025. g. 3. apr. 19:15 UTC

Tirgus saruna

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Gold Drops In Tariff Fallout -- Market Talk

2025. g. 3. apr. 18:39 UTC

Tirgus saruna

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

2025. g. 3. apr. 18:38 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 18:30 UTC

Top Ziņas

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

2025. g. 3. apr. 18:20 UTC

Tirgus saruna

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

2025. g. 3. apr. 18:18 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:17 UTC

Tirgus saruna

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

2025. g. 3. apr. 18:04 UTC

Tirgus saruna

US Sees More Job Openings in Construction, Transportation -- Market Talk

2025. g. 3. apr. 17:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Quanterix Corp Prognoze

Cenas mērķis

By TipRanks

115.77% augšup

Prognoze 12 mēnešiem

Vidējais 14.5 USD  115.77%

Augstākais 18 USD

Zemākais 10 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Quanterix Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

6.16 / 6.91Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

No Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.